TABLE 1.
Biotherapeutics included in EFA analysis.
| Drug | Indication a | Target |
|---|---|---|
| Remicade (infliximab) | RA | TNFa |
| Humira (adalimumab) | RA | TNFa |
| Stelara (ustekinumab) | Plaque psoriasis | IL-23/IL-12 |
| Skyrizi (risankizumab) | Plaque psoriasis | IL-23 |
| Benlysta (belimumab) | SLE | BLyS (BAFF) |
| Xolair (omalizumab) | Asthma | IgE |
| Herceptin (trastuzumab) | Breast Cancer | HER2 |
| Vectibix (panitumumab) | Colon Cancer | EGFR |
| Rybrevant (amivantamab) | NSCLC (EGFR exon 2) | EGFR/c-Met |
a
RA = rheumatoid arthritis, SLE = systemic lupus erythematosus.